COPENHAGEN (Reuters) – Novo Nordisk said on Thursday it will launch its hugely popular Wegovy obesity drug in Japan on Feb. 22 next year.
Most patients in Japan will pay 30% of medical expenses for Wegovy, in line with reimbursement for other drugs, a Novo Nordisk spokesperson said.
(Reporting by Jacob Gronholt-Pedersen; Editing by Susan Fenton)
